Business / Finance RSS Feed - Business / Finance

Seward achieves ISO14001 certification for minimising environmental impact

Seward Ltd., manufacturer of the world leading range of original Stomacher paddle blenders and accessories used in sample preparation for microbiological analysis, has received certification for ISO14001. [More]
PCI acquires Biotec Services International

PCI acquires Biotec Services International

PCI is pleased to announce it has acquired Biotec Services International. Biotec is a leading provider of Clinical Trial Services and Temperature Controlled Pharmaceutical Services headquartered in Bridgend, Wales in the United Kingdom. [More]
Providence Service to acquire CCHN Group Holdings

Providence Service to acquire CCHN Group Holdings

The Providence Service Corporation, a leader in the management and provision of human social services, innovative global employment services and non-emergency transportation through a variety of government-sponsored programs, announced today that it has entered into an agreement to acquire CCHN Group Holdings, Inc. ("Matrix Medical Network" or "Matrix"), a Scottsdale, Arizona provider of in-home health assessment and care management services and a portfolio company of Welsh, Carson, Anderson & Stowe XI, L.P. ("Welsh Carson"). [More]
Zimmer, MiMedx ink distribution agreement

Zimmer, MiMedx ink distribution agreement

MiMedx Group, Inc., an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has entered into a distribution agreement with Zimmer, Inc. [More]
Sigma-Aldrich enters into new gene editing partnership with U-M Medical School's Vector Core

Sigma-Aldrich enters into new gene editing partnership with U-M Medical School's Vector Core

Sigma-Aldrich Corporation announced today it has entered into a new gene editing partnership with the University of Michigan Medical School's Vector Core. Under the partnership, Sigma-Aldrich will provide the Vector Core with Sigma CRISPR technology, experimental design consultation, and dedicated gene editing bioinformaticians. [More]
Sanofi, MyoKardia partner to develop targeted therapeutics for cardiomyopathies

Sanofi, MyoKardia partner to develop targeted therapeutics for cardiomyopathies

Sanofi and MyoKardia, Inc., a privately-held company leading the development of precision therapies for genetic heart disease, announced today a worldwide collaboration to discover and develop first-of-its-kind targeted therapeutics for heritable heart diseases known as cardiomyopathies, the most common forms of heart muscle disease. [More]
Twinlab Consolidation becomes wholly-owned subsidiary of Twinlab Consolidated Holdings

Twinlab Consolidation becomes wholly-owned subsidiary of Twinlab Consolidated Holdings

As announced on August 11, 2014, Twinlab Consolidation Corporation completed its first transaction with the acquisition of Twinlab Corporation. Today, TCC announces the successful completion of its merger into Twinlab Consolidated Holdings Inc., resulting in TCC becoming a wholly-owned subsidiary of TLCC. [More]
3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio Inc., a leading biotechnology company based in China focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has entered into an exclusive license agreement with JenKem Technology Co., Ltd for the development, manufacturing and marketing in Mainland China of PEG-irinotecan, a long-acting polymer-drug conjugate which inhibits topoisomerase I (Topo-I). [More]
Denovo gains all rights from Lilly to develop, manufacture and commercialize enzastaurin drug

Denovo gains all rights from Lilly to develop, manufacture and commercialize enzastaurin drug

Denovo Biopharma, LLC, today announced that it has acquired enzastaurin, a late-stage oncology drug, from Eli Lilly and Company. Denovo gains all rights to develop, manufacture and commercialize enzastaurin globally, including transfer of all intellectual property and other rights, data, and information. [More]
Lilly, AstraZeneca partner to co-develop and commercialize potential Alzheimer's disease treatment

Lilly, AstraZeneca partner to co-develop and commercialize potential Alzheimer's disease treatment

Eli Lilly and Company and AstraZeneca today announced an agreement to co-develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer's disease. [More]
New ACD European subsidiary aims to provide faster, enhanced support for local customers

New ACD European subsidiary aims to provide faster, enhanced support for local customers

Advanced Cell Diagnostics Inc., a technology and market leader in the field of molecular pathology and developer of cell and tissue-based analysis tools, has announced the establishment of a European subsidiary which will start business in October 2014. [More]
Danaher signs definitive transaction agreement with Nobel Biocare

Danaher signs definitive transaction agreement with Nobel Biocare

Danaher Corporation has entered into a definitive transaction agreement with Nobel Biocare Holding AG pursuant to which Danaher Corporation or one of its direct or indirect subsidiaries ("Danaher") will commence a tender offer for all publicly held registered shares of Nobel Biocare in an all-cash transaction valued at approximately $2.2 billion. [More]
ChromaDex signs NIAGEN supply agreement with Healthy Directions

ChromaDex signs NIAGEN supply agreement with Healthy Directions

ChromaDex Corp., an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today that it has entered into an ingredient supply agreement with Healthy Directions, a direct-to-consumer nutritional supplement retailer and wholly-owned subsidiary of Helen of Troy Limited. [More]
NSF, NIH, USDA receive more than $12 million in new EEID grants

NSF, NIH, USDA receive more than $12 million in new EEID grants

Ebola, MERS (Middle East Respiratory Syndrome), malaria, antibiotic-resistant infections: Is our interaction with the environment somehow responsible for their increased incidence? [More]
Cancer Research UK, CRT partner with Asterias to trail novel immunotherapy treatment for lung cancer

Cancer Research UK, CRT partner with Asterias to trail novel immunotherapy treatment for lung cancer

CANCER RESEARCH UK and Cancer Research Technology , the charity's development and commercialisation arm, have reached an agreement with Asterias Biotherapeutics, Inc., a biotechnology company in the emerging field of regenerative medicine, to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in subjects with non-small cell lung cancer. [More]
Beta-O2 receives grant from JDRF to study ßAir bio-artificial pancreas for treatment of T1D

Beta-O2 receives grant from JDRF to study ßAir bio-artificial pancreas for treatment of T1D

Beta-O2 announced today that it has received a $500K grant from JDRF. The grant will be used to help fund a $1M pilot human study of Beta-O2's ├čAir bio-artificial pancreas, in development as a treatment and potential cure for type 1 diabetes (T1D). [More]
Lucideon announces collaboration with Knight Mechanical Testing

Lucideon announces collaboration with Knight Mechanical Testing

Lucideon, an international provider of materials development, testing and assurance, and Knight Mechanical Testing, an independent mechanical testing laboratory, are pleased to announce that they have entered into a Marketing and Commercial Collaboration Agreement. The agreement means that both partners will now be to offer a complete portfolio of testing and analysis services to the orthopaedic industry. [More]
Kinex Pharmaceuticals acquires QuaDPharma

Kinex Pharmaceuticals acquires QuaDPharma

Kinex Pharmaceuticals Inc. today announced that it has completed the acquisition of QuaDPharma, LLC., a Western New York based privately-held company specializing in pharmaceutical manufacturing, analytical and support services to the pharmaceutical and biotech industries. Financial terms of the transaction were not disclosed. [More]
Triple-S Salud collaborates with Voxiva and TracFone Wireless to improve health, satisfaction

Triple-S Salud collaborates with Voxiva and TracFone Wireless to improve health, satisfaction

Triple-S Salud has partnered with TracFone Wireless, Inc. and Voxiva, Inc. to improve the health and satisfaction of their members by providing access to free cell phones and health messaging programs. [More]
Codman reaches exclusive distribution agreement with Pulsar Vascular to market PulseRider

Codman reaches exclusive distribution agreement with Pulsar Vascular to market PulseRider

Codman Neuro, part of DePuy Synthes Companies of Johnson & Johnson, today announced it has reached an exclusive distribution agreement with Pulsar Vascular to market and promote that company's PulseRider® in Europe, the Middle East and Africa. [More]